PriceTargets.com logo

Neon Therapeutics - NTGN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.07 As of 05/6/2020 01:00 AM ET
+0 (0.00%)
Get New Neon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTGN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Neon Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.07.

This chart shows the closing price for NTGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Neon Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/21/2020HC WainwrightReiterated RatingNeutral
1/21/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight$2.18
1/16/2020Robert W. BairdDowngradeOutperform ➝ Neutral
12/19/2019HC WainwrightReiterated RatingHold
11/27/2019HC WainwrightDowngradeBuy ➝ Neutral
11/26/2019Morgan StanleyDowngradeOverweight ➝ Sell
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Neon Therapeutics logo
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.07
Low: $3.07
High: $3.07

50 Day Range

MA: $3.03
Low: $2.77
High: $3.07

52 Week Range

Now: $3.07
Low: $0.88
High: $6.25

Volume

N/A

Average Volume

516,108 shs

Market Capitalization

$88.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Neon Therapeutics?

The following Wall Street analysts have issued stock ratings on Neon Therapeutics in the last twelve months:
View the latest analyst ratings for NTGN.

What is the current price target for Neon Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Neon Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Neon Therapeutics in the next year.
View the latest price targets for NTGN.

What is the current consensus analyst rating for Neon Therapeutics?

Neon Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NTGN.

What other companies compete with Neon Therapeutics?

Other companies that are similar to Neon Therapeutics include bluebird bio, Ginkgo Bioworks, enGene, Jasper Therapeutics and Kodiak Sciences. Learn More about companies similar to Neon Therapeutics.

How do I contact Neon Therapeutics' investor relations team?

Neon Therapeutics' physical mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company's listed phone number is 617-337-4701 and its investor relations email address is [email protected]. The official website for Neon Therapeutics is www.neontherapeutics.com. Learn More about contacing Neon Therapeutics investor relations.